COMP <GO>
RYTM vs LLY // EV/EBITDA & P/E VALUATION
Rhythm Pharmaceuticals Inc. (NASDAQ) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: RYTM 4
— LLY 9
■ METRIC PARITY
LAST: $93.07 (+1.20%) • MKT CAP: $6.41B
valuation
—
LAST: $1,373.70 (+6.63%) • MKT CAP: $1.29T
valuation
36.4x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RYTM VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | RYTM | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 89.70% | 83.64% | +6.06 | RYTM | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -29.60% | 32.36% | -61.96 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | 36.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -1.82% | 2.30% | -4.12 | LLY | /fcf-yield <GO> |
| Operating Margin | -60.00% | 40.21% | -100.21 | LLY | /operating-margins <GO> |
| Net Profit Margin | -0.10% | 31.90% | -32.00 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 45.80% | 45.51% | +0.29 | RYTM | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 14.33 | 9.29 | +5.04 | RYTM | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 9/9 | -4.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.77% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 51.6 | 66.6 | -15.00 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.96 | 0.51 | +0.45 | RYTM | /macro-sensitivity <GO> |
| Forward P/E Multiple | 33.0x | 26.3x | +6.75 | LLY | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $6.41B | $1.29T | -$1.29T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | RYTM REV | LLY REV | RYTM GROSS % | LLY GROSS % | RYTM FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $189.8M | $65.18B | 89.7% | 83.0% | -$116.6M | $16.81B |
| FY 2024 | $130.1M | $45.04B | 89.7% | 81.3% | -$113.9M | $8.82B |
| FY 2023 | $77.4M | $34.12B | — | 79.3% | -$139.6M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RYTM // BETA 0.96
LLY // BETA 0.51